RIPPLE THERAPEUTICS PRESENTS AT EURETINA
Hemal Mehta, MBBS, MD (Cantab.), presented Efficacy and safety of the low dose dexamethasone IBE-814 IVT Implant for diabetic macular edema and retinal vein occlusion: Results of a first-in-human Phase 2 trial, at Euretina Congress in Barcelona, Spain, September 19-22, 2024.
Canadian Business Wendy Naimark, October 20, 2025 https://canadianbusiness.com/sponsored/why-a-homegrown-biotech-sector-matters/ Canada has the talent and innovation to lead in biotech, but without stronger investment, breakthroughs risk leaving our borders.
Ripple is featured (page 48) in LSO’s Success Stories publication, celebrating the groundbreaking work and inspiring contributions of Ontario’s life sciences organizations. View Presentation
